Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor
1998

Effective Treatment of Advanced Breast Cancer with Vinorelbine and Other Drugs

Sample size: 53 publication Evidence: moderate

Author Information

Author(s): GV Komek, K Haider, W Kwasny, F Lang, G Krauss, M Hejnal, M Raderer, G Weinlinder, D Depisch, W Scheithauer

Primary Institution: Vienna University Medical School

Hypothesis

The study investigates the efficacy and tolerance of vinorelbine, 5-fluorouracil, and leucovorin plus G-CSF in advanced breast cancer.

Conclusion

The combination of vinorelbine, 5-fluorouracil, and leucovorin plus G-CSF is an effective first-line treatment for advanced breast cancer with modest overall toxicity.

Supporting Evidence

  • The overall response rate was 59% for chemotherapeutically naive patients.
  • Median time to progression was 10.5 months in previously untreated patients.
  • Granulocytopenia was the most frequent and dose-limiting side effect.

Takeaway

Doctors tested a new medicine for women with advanced breast cancer, and it helped many of them feel better without making them too sick.

Methodology

A phase II trial was conducted with 53 patients receiving a combination of vinorelbine, 5-fluorouracil, leucovorin, and G-CSF.

Limitations

The study had a small sample size and was limited to patients aged 75 years or younger.

Participant Demographics

Median age was 55 years, with a range of 29-75 years; 37 patients were previously untreated.

Statistical Information

Confidence Interval

95% confidence interval 42-75%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication